{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T05:38:55Z","timestamp":1774330735240,"version":"3.50.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T00:00:00Z","timestamp":1604016000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T00:00:00Z","timestamp":1604016000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Acquired hemophilia A is a rare autoimmune disease with clinically often significant bleeding diathesis resulting from circulating autoantibodies inhibiting coagulation factor VIII. Half of acquired hemophilia A cases are associated with an underlying disorder, such as autoimmune diseases, cancer, or use of certain drugs, or occur during pregnancy and in the postpartum period. In the other half, no underlying cause is identified. An association of acquired hemophilia A with plasma cell neoplasm seems to be extremely rare.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>We describe a case of a 77-year-old Swiss Caucasian man who was diagnosed with acquired hemophilia A and smoldering multiple myeloma as an underlying cause. Acquired hemophilia A was treated with prednisolone, cyclophosphamide, and immunoadsorption. Extensive workup revealed a plasma cell neoplasm as the only disorder associated with or underlying the acquired hemophilia A. For long-term control of acquired hemophilia A, we considered treatment of the plasma cell neoplasm necessary, and a VRD (bortezomib, lenalidomide, and dexamethasone) regimen was initiated. Due to multiple complications, VRD was reduced to VRD-lite after two cycles. After nine cycles of induction therapy and five cycles of consolidation therapy, the patient is in complete remission of his acquired hemophilia A and very good partial remission of the plasma cell neoplasm. We conducted a literature review to identify additional cases of this rare association and identified 15 other cases. Case descriptions, including the sequence of occurrence of acquired hemophilia A and plasma cell neoplasm , treatment, evolution, and outcome are presented.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion and conclusions<\/jats:title><jats:p>Our case, together with 15 other cases described in the literature, underscore the possibility of plasma cell neoplasm as an underlying cause of acquired hemophilia A. Physicians should consider including protein electrophoresis, immunofixation, and analysis of free light chains in laboratory diagnostics when treating a patient with acquired hemophilia A. The occurrence of excessive and unexplained bleeding in patients diagnosed with plasma cell neoplasm should raise suspicion of secondary acquired hemophilia A and trigger the request for coagulation tests, particularly in patients treated with immunomodulatory drugs such as thalidomide or lenalidomide. Additionally, early intervention with immunoadsorption can be lifesaving in cases with high-titer factor VIII inhibitors, especially when surgical interventions are necessary.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13256-020-02505-7","type":"journal-article","created":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T00:04:06Z","timestamp":1604016246000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Acquired hemophilia A and plasma cell neoplasms: a\u00a0case report and review of the\u00a0literature"],"prefix":"10.1186","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3284-8308","authenticated-orcid":false,"given":"Katarzyna A.","family":"Jalowiec","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Andres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Behrouz Mansouri","family":"Taleghani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albulena","family":"Musa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Dickenmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Angelillo-Scherrer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia","family":"Rov\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna A.","family":"Kremer Hovinga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,10,30]]},"reference":[{"issue":"7","key":"2505_CR1","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/ajh.24777","volume":"92","author":"R Kruse-Jarres","year":"2017","unstructured":"Kruse-Jarres R, et al. Acquired hemophilia A: updated review of evidence and treatment guidance. Am J Hematol. 2017;92(7):695\u2013705.","journal-title":"Am J Hematol"},{"issue":"3","key":"2505_CR2","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.critrevonc.2007.12.004","volume":"66","author":"M Franchini","year":"2008","unstructured":"Franchini M, et al. Acquired factor VIII inhibitors in oncohematology: a systematic review. Crit Rev Oncol Hematol. 2008;66(3):194\u20139.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"6","key":"2505_CR3","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1182\/blood-2004-05-1811","volume":"105","author":"H Zeitler","year":"2005","unstructured":"Zeitler H, et al. Treatment of acquired hemophilia by the Bonn-Malmo protocol: documentation of an in vivo immunomodulating concept. Blood. 2005;105(6):2287\u201393.","journal-title":"Blood."},{"issue":"2","key":"2505_CR4","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/bjh.15261","volume":"182","author":"EK O\u2019Donnell","year":"2018","unstructured":"O\u2019Donnell EK, et al. A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. Br J Haematol. 2018;182(2):222\u201330.","journal-title":"Br J Haematol"},{"issue":"11","key":"2505_CR5","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1172\/JCI105294","volume":"44","author":"HI Glueck","year":"1965","unstructured":"Glueck HI, Hong R. A circulating anticoagulant in gamma-1A-multiple myeloma: its modification by penicillin. J Clin Invest. 1965;44(11):1866\u201381.","journal-title":"J Clin Invest"},{"issue":"2","key":"2505_CR6","first-page":"173","volume":"160","author":"LS Loftus","year":"1994","unstructured":"Loftus LS, Arnold WN. Acquired hemophilia in a patient with myeloma. West J Med. 1994;160(2):173\u20136.","journal-title":"West J Med"},{"issue":"2","key":"2505_CR7","first-page":"350","volume":"21","author":"RB Stricker","year":"1994","unstructured":"Stricker RB, Barlogie B, Kiprov DD. Acquired factor VIII inhibitor associated with chronic interferon-alpha therapy. J Rheumatol. 1994;21(2):350\u20132.","journal-title":"J Rheumatol"},{"issue":"5","key":"2505_CR8","doi-asserted-by":"crossref","first-page":"730","DOI":"10.5858\/2000-124-0730-AHIPWH","volume":"124","author":"S Sallah","year":"2000","unstructured":"Sallah S, Nguyen NP, Abdallah JM, Hanrahan LR. Acquired hemophilia in patients with hematologic malignancies. Arch Pathol Lab Med. 2000;124(5):730\u20134.","journal-title":"Arch Pathol Lab Med"},{"issue":"5","key":"2505_CR9","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/j.1365-2516.2005.01136.x","volume":"11","author":"PA Holme","year":"2005","unstructured":"Holme PA, Brosstad F, Tj\u00f8nnfjord GE. Acquired haemophilia: management of bleeds and immune therapy to eradicate autoantibodies. Haemophilia. 2005;11(5):510\u20135. https:\/\/doi.org\/10.1111\/j.1365-2516.2005.01136.x .","journal-title":"Haemophilia"},{"issue":"2","key":"2505_CR10","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1007\/s12185-009-0363-9","volume":"90","author":"I Sari","year":"2009","unstructured":"Sari I, et al. Multiple myeloma presenting with acquired factor VIII inhibitor. Int J Hematol. 2009;90(2):166\u20139.","journal-title":"Int J Hematol"},{"issue":"22","key":"2505_CR11","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1182\/blood.V114.22.1307.1307","volume":"114","author":"O Decaux","year":"2009","unstructured":"Decaux O, Guillet B, Millet A, et al. Acquired hemophilia associated with smoldering myeloma: demonstration that the monoclonal gammopathy acts as the factor VIII inhibitor [abstract]. Blood. 2009;114(22):1307.","journal-title":"Blood."},{"issue":"1","key":"2505_CR12","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s12185-011-0968-7","volume":"95","author":"J Muzaffar","year":"2012","unstructured":"Muzaffar J, et al. Rituximab and intravenous immunoglobulin (IVIG) for the management of acquired factor VIII inhibitor in multiple myeloma: case report and review of literature. Int J Hematol. 2012;95(1):102\u20136.","journal-title":"Int J Hematol"},{"issue":"5","key":"2505_CR13","first-page":"496","volume":"56","author":"M Saburi","year":"2015","unstructured":"Saburi M, et al. Development of acquired hemophilia A during treatment of multiple myeloma with lenalidomide [in Japanese]. Rinsho Ketsueki. 2015;56(5):496\u2013500.","journal-title":"Rinsho Ketsueki"},{"issue":"1","key":"2505_CR14","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s12288-013-0266-z","volume":"31","author":"C Ross","year":"2015","unstructured":"Ross C, et al. Management of acquired haemophilia bleed in the backdrop of multiple myeloma. Indian J Hematol Blood Transfus. 2015;31(1):151\u20133.","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"2","key":"2505_CR15","doi-asserted-by":"publisher","first-page":"184","DOI":"10.4274\/tjh.2016.0146","volume":"34","author":"V Innao","year":"2017","unstructured":"Innao V, et al. Disappearance of acquired hemophilia a after complete remission in a multiple myeloma patient. Turk J Haematol. 2017;34(2):184\u20135.","journal-title":"Turk J Haematol"},{"issue":"1","key":"2505_CR16","first-page":"109","volume":"43","author":"GP Br\u00e1s","year":"2017","unstructured":"Br\u00e1s GP, Pinto RJ, Carvalho MM, Fernandes SP, Andrade JJ, Guimar\u00e3es JE. Bortezomib: Potential Key Role in the Treatment of Multiple Myeloma-Related Acquired Hemophilia A. Semin Thromb Hemost. 2017;43(1):109\u201312.","journal-title":"Semin Thromb Hemost"},{"issue":"1","key":"2505_CR17","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/hae.13355","volume":"24","author":"M Napolitano","year":"2018","unstructured":"Napolitano M, et al. Acquired haemophilia in cancer: a systematic and critical literature review. Haemophilia. 2018;24(1):43\u201356.","journal-title":"Haemophilia."},{"issue":"22","key":"2505_CR18","doi-asserted-by":"publisher","first-page":"3303","DOI":"10.2169\/internalmedicine.0915-18","volume":"57","author":"I Kawashima","year":"2018","unstructured":"Kawashima I, et al. Combined coagulopathy can induce both hemorrhagic and thrombotic complications in multiple myeloma. Intern Med. 2018;57(22):3303\u20136.","journal-title":"Intern Med"},{"issue":"2","key":"2505_CR19","first-page":"179","volume":"77","author":"E Sourdeau","year":"2019","unstructured":"Sourdeau E, et al. Acquired hemophilia A associated with bullous pemphigoid and multiple myeloma: a case report. Ann Biol Clin (Paris). 2019;77(2):179\u201383.","journal-title":"Ann Biol Clin (Paris)"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-020-02505-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13256-020-02505-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-020-02505-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,11]],"date-time":"2021-04-11T09:57:54Z","timestamp":1618135074000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-020-02505-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,30]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2505"],"URL":"https:\/\/doi.org\/10.1186\/s13256-020-02505-7","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,30]]},"assertion":[{"value":"10 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted in accordance with the fundamental principles of the Declaration of Helsinki.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"206"}}